Purpose: A high phase angle measured by the Nutriguard ® bioelectrical impedance analysis 2 device is associated with a reduced mortality risk in older people. This retrospective study 3 aims to analyze whether this association persists with the other devices that have been used in 4 our hospital. 5 Methods: This study encompasses all people 65 yrs and older who underwent a phase angle 6 measurement between 1990 and 2011 at the Geneva University Hospitals, with the RJL-101 ® 7 (RJL Systems), Xitron 4000B ® (Xitron Technologies), Eugedia ® (Eugédia-Spengler) and Bio-8 Z ® (Spengler). Diseases at the time of phase angle measurement were reported in the form of 9
Introduction 27
An increasing interest arises in the potential of phase angle to predict adverse outcomes 28 like mortality (1-3). Phase angle is a raw bioelectrical impedance analysis (BIA)-derived 29 parameter which may reflect cell size, cell membrane integrity and/or the distribution of water 30 in the extra-and intracellular compartments (4) (5). Mathematically, it can be obtained from 31 the arctangent of the reactance to resistance ratio measured by BIA. Thus, phase angle values 32 do not depend on equations and their inherent assumptions, in contrast to BIA-derived body 33 composition, i.e. fat mass and fat-free mass. 34 In a recently published cohort study, we have included all people ≥ 65 yrs who had 35 undergone a BIA measurement at the Geneva University Hospitals between 1990 and 2011 36 (n=3181) (6). Mortality was reported until December 2012. We have shown that the lower the 37 phase angle quartile at the last BIA measurement performed with the Nutriguard ® device 38 (n=1307) (Data Input GmbH, Darmstadt, Germany), the higher was the death risk, 39 independently of the co-morbidities (7). We had focused on the measurements performed 40 with the Nutriguard ® device because 1) this device is still used in our hospital, and 2) phase 41 angle reference values using the same brand of BIA device have been published (8) and 42 allowed us to standardize the values for age and body mass index (BMI).
43
However, we have not reported the association of mortality and the phase angle measured 44 by the other BIA devices that we have used over the time span of 21 years. The rationale of 45 performing additionally these analyses is that, in the absence of a gold standard, phase angle 46 values likely differ between devices. This retrospective study aims to analyze whether phase Material and methods 51 We included the remaining 1878 people of our previously described cohort study (6), 52 which encompassed all people ≥65 yrs who underwent a BIA measurement at the Geneva 53 University Hospitals between 1990 and 2011. This study population included hospitalized 54 and ambulatory patients followed in clinical routine by the nutrition unit, and healthy people 55 recruited for research purpose in leisure clubs, the hospital staff, at fun runs and through 56 advertisement in local newspapers. The proportion of hospitalized patients was about 50% 57 (n=967). BIA measurements were performed at 50kHz and 0.8 mA, while the subject was 58 lying in the supine position with electrodes placed on the right hand, wrist, angle and foot.
59
The following devices were used: RJL-101 ® (1990 to 1995) (RJL Systems, Inc., Clinton 60 Township MI, USA), Xitron 4000B ® (1990 to 2011) (Xitron Technologies, San Diego, CA, 61 USA), Eugedia ® (1994 to 2000) (Eugédia-Spengler, Cachan, France) and Bio-Z ® (1996 to 62 2002) (Spengler, Paris, France). All devices were calibrated for phase angle with a 63 calibration jig (CJ 4000, Xitron Technologies, San Diego, CA, USA), before their use in our 64 institution. A limit of ±2° for phase angle and ±5Ω for impedance was tolerated at 50 kHz. To 65 test method agreement, we had measured the phase angle values of 8 healthy people with the 66 RJL-101 ® , the Xitron ® , and the Bio-Z ® , without changing the position of the people nor the 67 placement of the electrodes. Method agreement, calculated as the mean phase angle difference 68 (2SD) obtained from the Bio-Z ® minus the RJL-101 ® or the Xitron ® , was -1.49° (0.45) and -69 1.50 (0.24), respectively. We also calculated fat-free mass with the Geneva formula (9), 70 which was validated against DXA specifically in older persons (10). Fat mass was obtained 71 by subtracting fat-free mass from body weight. Fat-free mass index and fat mass index were 72 calculated as follows: fat-free mass or fat mass (kg)/body height (m) 2 .
73
Date of death was considered until December 2012, and retrieved from the hospital 74 computer database, the death registry of the state of Geneva and the Swiss National Cohort 75 (11). We reported co-morbidities at the time of the BIA measurement in the form of the 76 Cumulative Illness Rating Scale (CIRS) (12). It rates 14 systems and organs from 0 (healthy) to 4 (severe disease needing immediate intervention or hospitalization), and takes into account 78 lifestyle modes as smoking and alcohol consumption. Its final score ranges from 0 (healthy) 79 to 56 points. 
Results

95
The characteristics of the study subjects measured by the different BIA devices are shown 96 in table 1. They were significantly different regarding age, body mass index, co-morbidities 97 and phase angle.
98
The small number of deaths in women (n=16) and men (n=39) who underwent a BIA 99 measurement by Xitron 4000B precluded the use of sex-specific phase angle quartiles in the 100 Cox regressions. We thus focused on the three other devices (n=1683). In sex-specific 101 univariate Cox regressions, the association between phase angle quartiles measured with the 102 Bio-Z ® and RJL-101 ® devices and mortality could be highlighted, although the cut-off quartiles differed between the BIA devices (table 2). No associatation between phase angle 
